Relaxation of policy to obligate to turn in bioequivalence test data on drug reassessment
Data of bioequivalence tests must have been turned in reassessment of drugs so far, but a regulation will be relaxed that it need to conditionally be turned in depending on target products for the reassessment.
The Ministry of Food and Drug Safety announced a policy to turn in bioequivalence tes...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
